YUVEZZI
Launchcarbachol and brimonidine tartrate
NDAOPHTHALMICSOLUTION/DROPS
Approved
Jan 2026
Lifecycle
Launch
Competitive Pressure
0/100
Data completeness
2/8 — Basic
Drug data last refreshed 22h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
YUVEZZI is a fixed-dose ophthalmic solution combining carbachol (a cholinergic agonist) and brimonidine tartrate (an alpha-2 adrenergic agonist) delivered as drops. The combination targets intraocular pressure reduction and related ophthalmic conditions through dual mechanism action. The product represents a novel formulation approach to ophthalmology treatment.
Growth16.5 years to LOE
Early-stage launch with 13 linked positions indicates active team building across commercial and medical affairs functions.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
YUVEZZI launch creates immediate career opportunities across 5 regional MSL roles and cross-functional teams in commercial and medical affairs. The product's novel fixed-dose combination and extended patent protection offer stability for mid-to-long-term career development in specialty ophthalmology.
Medical Science Liaison (Midwest)Medical Science Liaison (Northeast)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.